Hydab 500mg Capsule contains Hydroxyurea, an antineoplastic agent used primarily in the treatment of various hematologic disorders. Hydroxyurea acts by inhibiting ribonucleotide reductase, leading to the suppression of DNA synthesis and cell proliferation. This mechanism makes it effective in managing conditions such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, and sickle cell anemia. In sickle cell anemia, Hydroxyurea increases fetal hemoglobin production, thereby reducing the frequency of painful crises and the need for blood transfusions. Hydab 500mg is administered orally and should be taken exactly as prescribed by a healthcare professional. Dosage adjustments may be necessary based on patient response and hematologic parameters. Common side effects include bone marrow suppression, gastrointestinal disturbances, and dermatologic reactions. Regular monitoring of complete blood counts and renal and hepatic function is essential during therapy to detect potential adverse effects early. Patients should be advised to avoid pregnancy during treatment due to potential teratogenicity. Hydab 500mg Capsule is contraindicated in patients with hypersensitivity to Hydroxyurea and those with severe bone marrow suppression. Proper adherence to prescribed dosing and monitoring protocols ensures optimal therapeutic outcomes while minimizing risks.